Faculty of medicine
Asyut, Assiut University, 71515, Egypt
NCT Number: NCT06380998
Over the last decade, awareness of the effects of hydrocarbon fuels on neurodegenerative disorders has increased significantly, as they are ubiquitous environmentally toxic chemicals that affect the central nervous system and result in irreversible neuronal damage, as many hydrocarbons can cross the blood-brain barrier through multiple pathways and cause direct toxicity.
Trial opening soon.
Get Notified18 year–50 year
All sexes
Observational
Asyut, Assiut University, 71515, Egypt
Petrol stations are establishments that retail liquid fuels derived from petroleum, alcohol, and other automotive fuels, with equipment available for their measurement and storage. This process, linked to gasoline distribution, can be a significant source of volatile organic compounds (VOCs), such as benzene, toluene, ethylbenzene, and xylene isomers (BTEX), the primary volatile hydrocarbons derived from petroleum.
Headache, fatigue, dizziness, respiratory tract infections, skin allergies, eye infections, and impairment of memory have been experienced by a few people immediately following exposure to some solvents. CNS depression is a common physiological outcome caused by high exposure to some VOCs. General anaesthetic effects, and as a most severe outcome, unconsciousness and, in some cases, death, may occur at the end.
Long-term exposure to organic solvents may cause permanent central nervous system disturbances, a condition called chronic solvent encephalopathy (CSE).
Cognitive symptoms and neuropsychological signs, or issues with memory, focus, and learning, are the hallmarks of CSE, which is underdiagnosed and characterized by these symptoms as well as possible side effects like headaches, fatigue, balance issues, and mild depression. If exposure stops, though, the illness will not worsen.
We are discovering more about the importance of nutrition and its impact on an individual's susceptibility to illness progression. Diet has been suggested to have an important role in cognitive health and the development of dementia. However, most of the intervention studies conducted to date have mainly assessed the effect of dietary supplements on cognitive function.
The toxicity of inhaled vapours is due to their biotransformation into reactive oxygen species, and several studies have highlighted the capacity of whey protein to increase glutathione (GSH), suggesting that this complex mixture is capable of boosting GSH synthesis, thus reducing oxidative stress.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Whey, the supernatant of yogurt and a byproduct of cheese, is rich in protein and consists of β-lactalbumin, α-lactoglobulin, immunogloblin, bovine serum albumin, and other minor proteins. Whey protein is a globally consumed food material and is well known for its health benefits
Time frame: 1 year
for psychological assessment through symptom check list 90 (revised) and cognitive function through the Mini Mental State Examination (30 points: 25-30: normal; 21-24: mild cognitive impairment; 10-20: moderate; and 0-9: severe) and Wecksler memory scale (higher score indicates better performance, while lower score indicates memory impairment)
Time frame: 1 year
urinary metabolites for BTEX through GS-MS
Time frame: 1 year
20 g of whey protein 3 times per week for 8 weeks will be given to workers with cognitive difficulties
Time frame: 1 year
relationship between nutritional status, psychological symptoms, and cognitive difficulties through statistics
Contact information is provided by the study sponsor or research team.
Doaa Almaz, lectur
CONTACT
Gehad H Eisa, Assi. lectur
CONTACT
Assiut University
Other
Effects of Petroleum Compounds on Psychological Health, Cognitive Functions, and the Possible Ameliorating Effect of Whey Protein in a Sample of Petrol Station Workers in Assiut Governorate
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05818423
Cognition Disorders, Cognitive Decline
San Francisco, California, United States
View Trial DetailsNCT05497427
Alzheimer Disease, Brain Diseases
Palo Alto, California, United States
View Trial DetailsNCT06256666
Cognitive Deterioration
Volterra, Pisa, Italy
View Trial DetailsNCT06056934
Cognitive Deterioration
Nîmes, CHU de Nîmes, France
View Trial Details